MRNS Overview
Upcoming Projects (MRNS)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (MRNS)
-
Discussing the potential of Marinus' ganaxolone in Refractory Status Epilepticus and the RAISE trial
Tickers: MRNS, SAGE
Executed On: Oct 03, 2023 at 02:30 PM EDT -
A look at the recent approval of Marinus’ Ztalmy (ganaxalone) and potential use in CDKL5 deficiency disorder
Ticker: MRNS
Executed On: Apr 04, 2022 at 10:00 AM EDT
Expired Projects (MRNS)
-
Preview ph3 ganaxolone in Refractory Status Epilepticus (RSE) for 1Q24: Examining ph.2 data and RSE landscape
Tickers: MRNS, SAGE
Execute By: Oct 06, 2023 -
Analyzing Marinus’ Ganaxolone in treating Postpartum Depression, after its Phase 2 Magnolia and Amaryllis trials data
Tickers: MRNS, SAGE
Execute By: Aug 28, 2018
Upcoming & Overdue Catalysts (MRNS)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (MRNS)
-
Marinus (MRNS) to Commence Phase 2 Study Evaluating Ganaxolone IV in Life-Threatening Epilepsy in H1 2017
Ticker: MRNS
Occurred on: Aug 01, 2017 -
Marinus Pharmaceuticals (MRNS) Receives Orphan Drug Designation From FDA on Ganaxolone in treating Fragile X Syndrome
Ticker: MRNS
Occurred on: Jan 03, 2017 -
Ganaxolone IV data anticipated in the second half of 2016
Ticker: MRNS
Occurred on: Oct 24, 2016 -
Phase 2 data of Ganaxolone for Fragile X Syndrome due 1Q 2016
Ticker: MRNS
Occurred on: Jun 28, 2016 -
Results from Phase 2 Exploratory Clinical Study Support Continued Development of Ganaxolone in Fragile X Syndrome
Ticker: MRNS
Occurred on: Jun 28, 2016 -
Marinus Pharmaceuticals Doses First Subject in Phase 1 Clinical Trial for Ganaxolone IV
Ticker: MRNS
Occurred on: Jun 22, 2016 -
Marinus Pharmaceuticals Announces Top-Line Results from Phase 3 Trial in Adult Focal Onset Seizures
Ticker: MRNS
Occurred on: Jun 13, 2016
Strategic Initiatives (MRNS)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
